Finch Therapeutics Group (FNCH) Peer Comparison

$7.45

$6.24 (515.70%)

As on 01-Jun-2026 09:30EDT

Market cap

$15 Mln

Revenue (TTM)

$6 Mln

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Edit

	Finch Therapeutics Group (FNCH)	NovaBay Pharmaceuticals (NBY)
Market cap ($ Mln)	15	52
Revenue ($ Mln)	6	2
Net Profit ($ Mln)	-13.88	522.59
Net Margin (%)	-248.98	21,217.70
RoE (%)	-86.83	744.12
Price to Earnings	--	--
Price-To-Book	0.84	0.24

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Finch Therapeutics Group (FNCH)	NovaBay Pharmaceuticals (NBY)
Operating Revenue	--	9.78
Cost of Revenue	0.17	3.30
Gross Profit	-0.17	6.48
Operating Expenses	18.69	12.32
Operating Profit (EBIT)	-18.86	-5.84
Other Income	--	--
Profit before Tax	-13.88	-7.21
Provision for Tax	--	--
Profit after Tax (Net Income)	-13.88	-7.22
Minority Interest	--	--
Consolidated Profit	--	-8.61

Liabilities ($ Mln)

	Finch Therapeutics Group (FNCH)	NovaBay Pharmaceuticals (NBY)
Shareholder's Funds	9.08	-0.13
Minority Interest	--	--
Non-Current Liabilities	37.50	0.71
Current Liabilities	3.17	2.84
Total Liabilities	49.75	3.42

Assets ($ Mln)

	Finch Therapeutics Group (FNCH)	NovaBay Pharmaceuticals (NBY)
Non-Current Assets	38.98	1.49
Current Assets	10.77	1.94
Total Assets	49.75	3.42
Total Debt*	27.79	1.67
Net Current Assets	--	-0.91

Cashflow ($ Mln)

	Finch Therapeutics Group (FNCH)	NovaBay Pharmaceuticals (NBY)
Cash From Operating Activities	--	-5.18
Cash Flow from Investing Activities	--	1.06
Cash from Financing Activities	--	1.50
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Finch Therapeutics Group (FNCH)	NovaBay Pharmaceuticals (NBY)
ROCE (%)	-30.88	-190.15
ROE (%)	-86.83	-453.56
ROA (%)	-26.40	-115.97
EBIT Margin (%)	--	--
Net Margin (%)	--	-73.85
Cash Profit Margin (%)	--	--

Growth Ratios

	Finch Therapeutics Group (FNCH)	NovaBay Pharmaceuticals (NBY)
Revenue Growth (%)	--	-0.06
EBIT Growth (%)	--	--
Net Profit Growth (%)	81.44	25.07
EPS Growth (%)	0.81	0.85
Book Value Growth (%)	--	--

Valuation Ratios

	Finch Therapeutics Group (FNCH)	NovaBay Pharmaceuticals (NBY)
Price / Earnings	--	-0.41
Price / Book Value	--	-22.76
Dividend Yield (%)	--	--
EV/EBITDA	--	-0.71
Market Cap ($ Cr)	--	--

Solvency Ratios

	Finch Therapeutics Group (FNCH)	NovaBay Pharmaceuticals (NBY)
Debt to Equity	3.06	-12.96
Short term debt to equity ratio	0.25	-7.47
Current Ratio	3.39	0.68
Quick Ratio	--	0.41
Interest Coverage	--	-6.98

Operating Efficiency Ratios

	Finch Therapeutics Group (FNCH)	NovaBay Pharmaceuticals (NBY)
Debtors to sales (%)	--	3.98
Asset Turnover	--	1.57
Receivable days	--	21.43
Inventory Days	--	201.55
Payable days	303.33	97.01
Cash Conversion Cycle	--	125.97

Annual
Quarterly